User:SDZeroBot/NPP sorting/STEM/Chemistry: Difference between revisions

Revision as of 13:49, 7 August 2025

Revision as of 01:47, 8 August 2025

Line 1:

{{User:SDZeroBot/NPP sorting/header|count=12|date=78 August 2025|ts=1301:4947, 78 August 2025 (UTC)}}

{| class="wikitable sortable"

Line 14:

| Qing-Yun Chen ({{zh|s=陈庆云|p=Chén Qìngyún}}; 25 January 1929 – 2 March 2023) was a Chinese [[organic chemist]] and member of the [[Chinese Academy of Sciences]], specializing in the field of organic fluorine chemistry.

| Start

| data-sort-value=82798288 | [[Special:Contribs/Tokisaki Kurumi|Tokisaki Kurumi]] (82798288)

|

|-

Line 55:

| [[225Ac-PSMA-R2]] <small>(Investigational radiopharmaceutical)</small>

| 225Ac-PSMA-R2 is an investigational [[radiopharmaceutical]] developed by [[Novartis]] for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and [[metastatic castration-resistant prostate cancer]] (mCRPC). It is a [[targeted alpha therapy]] (TAT) combining [[actinium-225]] (225Ac), an alpha-emitting [[radionuclide]], with PSMA-R2, a small-molecule [[ligand]] targeting [[prostate-specific membrane antigen]] (PSMA), a protein overexpressed in prostate cancer cells.

| C

| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)

|

|-

| 2025-07-29

| [[OpRegen]] <small>(Allogeneic cell therapy)</small>

| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.

| C

| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)

Line 84 ⟶ 77:

| On July 18, 2025, an explosion occurred at the [[Los Angeles County Sheriff's Department]] (LASD) Biscailuz Center training facility in [[East Los Angeles, California]].&nbsp;The explosion killed three police officers and is the deadliest incident for the LASD since 1857.

| Start

| data-sort-value=176177 | [[Special:Contribs/DesertIV|DesertIV]] (176177)

| [[Wikipedia:Articles for deletion/2025 Los Angeles County Sheriff's Department training facility explosion|Past AfD]]

|-

| 2025-0807-0529

| [[OpRegen]] <small>(Allogeneic cell therapy)</small>

| [[Dr. AbdelHamid Hussein Mohamed Gewaily]]

| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.

| Abdel Hamid Hussein Mohamed Gewaily is an Egyptian [[geophysicist]] and energy executive. He currently serves as Chairman and Managing Director of both PetroSlam Petroleum and Disouq Petroleum (PetroDesouk). Prior to these roles, he served as Vice Executive Managing Director for Agreements & Exploration at the Egyptian Natural Gas Holding Company (EGAS), overseeing strategic exploration and major international energy agreements.

| C

| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)

|

|-

| 2025-0708-2904

| [[Cinnabarinic acid]] <small>(Chemical compound)</small>

| Cinnabarinic acid is a [[metabolite]] formed through the oxidative processing of [[tryptophan]]. It is an endogenous metabolite of the [[kynurenine pathway]] of [[tryptophan]] catabolism, formed by oxidative dimerization of two molecules of [[3-hydroxyanthranilic acid]]. It functions both as a partial agonist at type 4 [[metabotropic glutamate receptors]] (mGlu₄) and as a ligand for the [[aryl hydrocarbon receptor]] (AhR), with implications for [[neuroprotection]] and [[immunomodulation]].

| Start

| data-sort-value=1337 | [[Special:Contribs/Eng.adel85FlarpenX|Eng.adel85FlarpenX]] (1337)

|

|}

<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] ^{''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''} at 1301:4947, 78 August 2025 (UTC)</span>